Therapeutics News

CLEVELAND — The Cleveland Clinic’s biannual Medical Dermatology Therapy Update meeting is currently underway, bringing news about medical therapies available in the dermatology space.

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

Almirall has entered into a licensing agreement with Eloxx Pharmaceuticals Inc. to develop and commercialize ZKN-013 for the treatment of orphan dermatological diseases, according to an Almirall press release.

AbbVie reported a worldwide net revenue of $12.31 billion in the first quarter of 2024 despite Humira sales dropping due to biosimilar competition, according to a company press release.

Healio has compiled April’s most-read news in dermatology.

The use of thermal imaging and the ALT-70 prediction model were helpful in differentiating cellulitis from pseudocellulitis, reducing misdiagnosis, according to a study.

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.

Hepatic adverse events with bimekizumab were low and consistent through 2 years of treatment among patients with moderate to severe psoriasis, according to a study.

ARCA biopharma and Oruka Therapeutics have entered into a definitive merger agreement and will now operate under Oruka Therapeutics, ARCA announced in a press release.

Healio has compiled March’s most-read news in dermatology.